These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331 [TBL] [Abstract][Full Text] [Related]
8. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. Casterella PJ; Revenaugh JR; Burke JL; Pearson RR; Bair TL; May HT; Horne B; Anderson JL; Muhlestein JB J Invasive Cardiol; 2008 Mar; 20(3):94-8. PubMed ID: 18316822 [TBL] [Abstract][Full Text] [Related]
9. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P; Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315 [TBL] [Abstract][Full Text] [Related]
10. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. McCollam PL; Foster DA; Riesmeyer JS Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921 [TBL] [Abstract][Full Text] [Related]
11. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use. Pang JT; Fort S; Della Siega A; Cohen EA J Card Surg; 2002; 17(5):425-31. PubMed ID: 12630543 [TBL] [Abstract][Full Text] [Related]
12. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors. Ali A; Patil S; Grady KJ; Schreiber TL Catheter Cardiovasc Interv; 2000 Feb; 49(2):181-4. PubMed ID: 10642769 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention. Cheng JW Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors. Brouse SD; Wiesehan VG Ann Pharmacother; 2004 Nov; 38(11):1783-8. PubMed ID: 15383640 [TBL] [Abstract][Full Text] [Related]
15. Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction. Racine E Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S27-36. PubMed ID: 12434712 [TBL] [Abstract][Full Text] [Related]
16. A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention. Vakili BA; Kaplan RC; Slater JN; Sherman W; Ravi KL; Green SJ; Sanborn TA; Brown DL Am J Cardiol; 2003 Apr; 91(8):946-50. PubMed ID: 12686333 [TBL] [Abstract][Full Text] [Related]
17. Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction. Gruberg L; Suleiman M; Kapeliovich M; Hammerman H; Grenadier E; Boulus M; Amikam S; Markiewicz W; Beyar R J Invasive Cardiol; 2006 Feb; 18(2):59-62. PubMed ID: 16446517 [TBL] [Abstract][Full Text] [Related]
18. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
19. Acute profound thrombocytopenia following abciximab therapy. Bishara AI; Hagmeyer KO Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405 [TBL] [Abstract][Full Text] [Related]
20. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab. Coto H J Invasive Cardiol; 2000 Oct; 12(10):528-31. PubMed ID: 11022214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]